HRP20230239T1 - Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu - Google Patents
Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu Download PDFInfo
- Publication number
- HRP20230239T1 HRP20230239T1 HRP20230239TT HRP20230239T HRP20230239T1 HR P20230239 T1 HRP20230239 T1 HR P20230239T1 HR P20230239T T HRP20230239T T HR P20230239TT HR P20230239 T HRP20230239 T HR P20230239T HR P20230239 T1 HRP20230239 T1 HR P20230239T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally
- cell
- seq
- cells
- region
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 19
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title claims 17
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 17
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title claims 17
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 25
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 210000003289 regulatory T cell Anatomy 0.000 claims 8
- 230000000638 stimulation Effects 0.000 claims 7
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 102000000588 Interleukin-2 Human genes 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 5
- 210000002865 immune cell Anatomy 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- -1 CD44v7/8 Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100026720 Interferon beta Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 2
- 108090000171 Interleukin-18 Proteins 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
Claims (15)
1. Kimerni antigenski receptor (CAR) koji sadrži signalni peptid, domena za vezanje antigena TGF-β s varijabilnom teškom (VH) i varijabilnom lakom (VL) regijom antitijela, peptidnu razmaknicu, transmembransku domenu, i endodomenu koja emitira aktivacijski signal T stanicama nakon vezanja antigena; pri čemu se domena za vezanje antigena TGF-β specifično veže za rastvorni TGF-β i pri čemu:
(a) VH regija sadrži SEQ ID NO:5 kao HCDR1, SEQ ID NO:6 kao HCDR2; i SEQ ID NO:7 kao HCDR3 i VL regija sadrži SEQ ID NO:8 kao LCDR1, SEQ ID NO:9 kao LCDR2; i SEQ ID NO:10 kao LCDR3; ili
(b) VH regija sadrži SEQ ID NO:11 kao HCDR1, SEQ ID NO:12 kao HCDR2; i SEQ ID NO: 13 kao HCDR3 i VL regija sadrži SEQ ID NO:14 kao LCDR1, SEQ ID NO:15 kao LCDR2; i SEQ ID NO:16 kao LCDR3; ili
(c) VH regija sadrži SEQ ID NO:21 kao HCDR1, SEQ ID NO:22 kao HCDR2; i SEQ ID NO:23 kao HCDR3 i VL regija sadrži SEQ ID NO:24 kao LCDR1, SEQ ID NO:25 kao LCDR2; i SEQ ID NO:26 kao LCDR3; i
pri čemu CAR ima strukturu: S-X-PL-Y-PS-T-E ili S-Y-PL-X-PS-T-E pri čemu je S signalni peptid, X je VH, PL je peptidni povezivač, Y je VL, PS je peptidna razmaknica, T je transmembranska domena, i E je endodomena.
2. CAR prema patentnom zahtjevu 1(a), pri čemu VH regija sadrži SEQ ID NO:1 i VL regija sadrži SEQ ID NO:2.
3. CAR prema patentnom zahtjevu 1, pri čemu:
(a) VH regija prema patentnom zahtjevu 1(b) sadrži SEQ ID NO:3 i VL regija sadrži SEQ ID NO:4; ili
(b) VH regija prema patentnom zahtjevu 1(c) sadrži SEQ ID NO: 19 i VL regija sadrži SEQ ID NO:20.
4. CAR prema bilo kojem od patentnih zahtjeva 1–3, pri čemu:
(a) VH regija i VL regija su odvojene pomoću peptidnog povezivača; i/ili
(b) CAR dalje sadrži kostimulatornu regiju, opcionalno pri čemu je kostimulatorna regija između transmembranske domene i endodomene; i/ili
(c) transmembranska domena sadrži transmembransku domenu iz CD28; i/ili
(d) endodomena sadrži CD28 ili CD3 zeta signalnu domenu; pri čemu je opcionalno peptidni povezivač glicin-serinski povezivač.
5. CAR prema bilo kojem od patentnih zahtjeva 1(b), 1(c), 2, 3 ili 4, pri čemu je peptidni povezivač najmanje 4 aminokiseline.
6. CAR prema bilo kojem od patentnih zahtjeva 1–5, pri čemu:
(a) endodomena je CD3-zeta signalna domena; i/ili
(b) peptidna razmaknica sadrži: (i) manje od 50 aminokiselina; ili (ii) više od 50 aminokiselina; i/ili
(c) peptidna razmaknica sadrži zglobnu regiju molekula IgG; i/ili
(d) peptidna razmaknica sadrži zglobnu regiju i regiju CH2CH3 molekula IgG, pri čemu se opcionalno peptidna razmaknica sastoji od zglobne regije molekula IgG; i/ili
(e) CAR dalje sadrži peptid za detekciju, pri čemu je opcionalno peptid za detekciju peptid iz SEQ ID NO:17, 94, ili 95: i opcionalno: (i) peptid za detekciju je okružen povezivačima; i/ili (ii) peptid za detekciju je N-terminalni za VH i VL regije; i/ili (iii) peptid za detekciju je između signalnog peptida i domene za vezanje antigena.
7. CAR prema bilo kojem od patentnih zahtjeva 1–6, pri čemu:
(a) signalni peptid sadrži SEQ ID NO:18; i/ili
(b) CAR dalje sadrži domenu za vezivanje antigena specifičnu za molekulu raka, pri čemu opcionalno molekula raka sadrži Her2 ili sadrži CD19 ili CD20; ili
(c) CAR dalje sadrži domenu za vezivanje antigena specifičnu za molekulu raka, pri čemu se opcionalno domena za vezivanje antigena specifična za molekulu raka veže za CAIX, CD33, CD44v7/8, CEA, EGP-2, EGP-40, erb-B2, erbB3, erb-B4, FBP, fetalni acetiholinski receptor, GD2, GD3, Her2/neu, IL-13Ralpha2, KDR, k-laki lanac, LeY, L1 molekula stanične adhezije, MAGE-A1, mezotelin, MUC1, NKG2D ligande, onkofetalni antigen (h5T4), PSCA, PSMA, TAA koji su ciljni za mAb IgE, TAG-72, ili VEGF-R2.
8. Izolirana nukleinska kiselina koja kodira CAR prema bilo kojem od patentnih zahtjeva 1–7.
9. Stanica koja sadrži CAR prema bilo kojem od patentnih zahtjeva 1–7 ili nukleinska kiselina prema patentnom zahtjevu 8, pri čemu:
(A) opcionalno stanica dalje sadrži kimerni antigenski receptor (CAR) specifičan za rak, i opcionalno se CAR specifičan za rak specifično veže za: (i) Her2 ili (ii) specifično veže za CD19 ili CD20, pri čemu opcionalno stanica je imunološka stanica; i
(B) opcionalno: (a) stanica je T stanica, opcionalno CD4+ ili CD8+ T stanica; ili T regulatorna stanica; ili (b) stanica je stanica prirodni ubojica.
10. Stanica prema patentnom zahtjevu 9 za upotrebu u postupku za stimuliranje imunološkog odgovora, pri čemu navedeni postupak obuhvaća dovođenje u kontakt stanice prema patentnom zahtjevu 9 sa TGF-β, pri čemu opcionalno:
(i) stimuliranje imunološkog odgovora obuhvaća povećanje ekspresije i/ili lučenja imunostimulirajućih citokina i/ili molekula, pri čemu su opcionalno imunostimulirajući citokini i/ili molekule jedan ili više od TNF-α, IFN-β, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18 i faktora stimulacije kolonije granulocitnih makrofaga; ili (ii) stimuliranje imunološkog odgovora koji obuhvaća povećanje proliferacije imunoloških stanica, opcionalno pri čemu imunološke stanice su T stanice.
11. Stanica prema patentnom zahtjevu 9 za upotrebu u postupku za stimuliranje imunološkog odgovora, pri čemu navedeni postupak obuhvaća dovođenje u kontakt stanice prema patentnom zahtjevu 9 ili patentnom zahtjevu 10 sa TGF-β, pri čemu stanica je in vivo u subjektu kojem je potrebna imunološka stimulacija i opcionalno TGF-β je endogeni TGF-β proizveden u subjektu kome je potrebna imunološka stimulacija, pri čemu opcionalno:
(i) ljudski subjekt ima rak, fibrozu, ili otvorenu ranu, pri čemu opcionalno rak je melanom; (ii) ljudski subjekt ima malignitet B-stanica; ili (iii) ljudski subjekt ima čvrsti tumor; i pri čemu opcionalno:
(iv) postupak dalje obuhvaća davanje stanice ljudskom subjektu; i/ili (v) postupak dalje obuhvaća davanje TGF-β subjektu.
12. Ex vivo postupak za detektiranje TGF-β u otopini koja obuhvaća dovođenje u kontakt stanica prema patentnom zahtjevu 9 s otopinom i mjerenje imunološke stimulacije; pri čemu povećanje u imunološkoj stimulaciji ukazuje na prisutstvo TGF-β i odsustvo povećanja u imunološkoj stimulaciji ukazuje na odsustvo TGF-β, pri čemu opcionalno:
(i) imunološka stimulacija obuhvaća ekspresiju imunostimulirajućih citokina i/ili molekula, pri čemu opcionalno imunostimulirajući citokini i/ili molekule su jedan ili više od TNF-α, IFN-β, IFN-γ, IL-1, IL2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18 i faktora stimulacije kolonije granulocitnih makrofaga; ili (ii) imunološka stimulacija obuhvaća povećanje u proliferaciji imunoloških stanica, pri čemu opcionalno imunološke stanice su T stanice.
13. Postupak za dobivanje CAR prema bilo kojem od patentnih zahtjeva 1–7 koji obuhvaća eksprimiranje nukleotida koji kodira CAR u stanici.
14. Postupak za umnožavanje T stanica in vitro, pri čemu postupak obuhvaća dovođenje u kontakt T stanice prema patentnom zahtjevu 9B s sastavom koji sadrži TGF-β, pri čemu opcionalno sastav: (a) sadrži 1–50 ng/mL TGF-β; i/ili (b) sadrži IL-2 i opcionalno sastav sadrži 20–400 U/mL IL-2,
pri čemu opcionalno:
(a) (i) postupak dalje obuhvaća dovođenje u kontakt stanica s hraniteljskim stanicama, pri čemu opcionalno hraniteljske stanice su ozračene; ili (ii) postupak isključuje kontakt T stanica s hraniteljskim stanicama; i/ili
(b) T stanica je regulatorna T stanica, pri čemu opcionalno umnožene regulatorne T stanice sadrže manje od 10% neregulatornih T stanica.
15. Stanica prema patentnom zahtjevu 9B za upotrebu u postupku za liječenje bolesti ili patološkog stanja kod pacijenta,
pri čemu opcionalno: (a) stanica je regulatorna T stanica, pri čemu opcionalno bolest je: autoimuna bolest; ili (b) bolest je rak;
pri čemu opcionalno postupak dalje obuhvaća umnožavanje stanica in vitro postupkom koji obuhvaća dovođenje u kontakt stanice in vitro s sastavom koji sadrži TGF-β; pri čemu opcionalno: (a) sastav sadrži 1–50 ng/mL TGF-β; i/ili (b) sastav dalje sadrži IL-2, i opcionalno sastav sadrži 20–400 U/mL IL-2;
pri čemu opcionalno: (a) postupak dalje obuhvaća dovođenje u kontakt stanica s hraniteljskim stanicama, pri čemu opcionalno hraniteljske stanice su ozračene; ili (b) postupak isključuje kontakt T stanica s hraniteljskim stanicama;
pri čemu opcionalno T stanica je regulatorna T stanica, pri čemu opcionalno umnožene regulatorne T stanice sadrže manje od 10% neregulatornih T stanica;
pri čemu opcionalno autoimuna bolest je reumatoidni artritis; i
pri čemu opcionalno postupak dalje obuhvaća davanje TGF-β pacijentu.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248685P | 2015-10-30 | 2015-10-30 | |
PCT/US2016/059444 WO2017075433A1 (en) | 2015-10-30 | 2016-10-28 | Transforming growth factor-beta-responsive polypeptides and their methods for use |
EP16860930.3A EP3368571B1 (en) | 2015-10-30 | 2016-10-28 | Transforming growth factor-beta-responsive polypeptides and their methods for use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230239T1 true HRP20230239T1 (hr) | 2023-04-14 |
Family
ID=58631218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230239TT HRP20230239T1 (hr) | 2015-10-30 | 2016-10-28 | Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu |
Country Status (16)
Country | Link |
---|---|
US (2) | US11014980B2 (hr) |
EP (2) | EP3368571B1 (hr) |
JP (2) | JP7104624B2 (hr) |
KR (1) | KR20180092947A (hr) |
CN (2) | CN108884155B (hr) |
DK (1) | DK3368571T3 (hr) |
ES (1) | ES2935372T3 (hr) |
FI (1) | FI3368571T3 (hr) |
HR (1) | HRP20230239T1 (hr) |
HU (1) | HUE061424T2 (hr) |
LT (1) | LT3368571T (hr) |
PL (1) | PL3368571T3 (hr) |
PT (1) | PT3368571T (hr) |
RS (1) | RS64053B1 (hr) |
SI (1) | SI3368571T1 (hr) |
WO (1) | WO2017075433A1 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
RS64053B1 (sr) * | 2015-10-30 | 2023-04-28 | Univ California | Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu |
AU2017247796A1 (en) * | 2016-04-05 | 2018-09-27 | Glaxosmithkline Intellectual Property Development Limited | Inhibition of TGFBeta in immunotherapy |
US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
EP3646878A4 (en) * | 2017-06-30 | 2021-03-24 | Kolon Life Science, Inc. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS |
CN109486745A (zh) * | 2017-09-12 | 2019-03-19 | 中国人民解放军第三军医大学第附属医院 | Fg-4592在促进表皮干细胞迁移方面的应用 |
CA3088832A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec B.V. & Co. KG | Regulatory t cell expressing a chimeric antigen receptor |
GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
CN111748043B (zh) * | 2020-07-03 | 2022-09-02 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
CN112500491B (zh) * | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
WO2023023602A1 (en) * | 2021-08-19 | 2023-02-23 | Boan Boston Llc | Fusion proteins for dephosphorylating proteins that regulate t cell activation through the tcr signaling pathway |
WO2023201206A1 (en) * | 2022-04-11 | 2023-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine adaptor proteins and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
US5543293A (en) | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
WO1998050432A1 (en) | 1997-05-07 | 1998-11-12 | Bristol-Myers Squibb Company | Recombinant antibody-enzyme fusion proteins |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US7066469B2 (en) | 2002-08-06 | 2006-06-27 | University of Kentucky Research Foundation Board of Supervisors of Louisiana State University | Seal assembly for machinery housing |
UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
WO2005000200A2 (en) * | 2003-05-09 | 2005-01-06 | Sugen, Inc. | Novel kinases |
RU2006120483A (ru) | 2003-11-13 | 2007-12-20 | Дженентек, Инк. (Us) | Скрининг-анализы и способы лечения опухоли |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
WO2006046661A1 (ja) | 2004-10-28 | 2006-05-04 | Osaka University | インターロイキン-6阻害剤 |
ES2905923T3 (es) | 2005-02-08 | 2022-04-12 | Genzyme Corp | Anticuerpos de TGFbeta |
KR20080082618A (ko) | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Alk5 조절제를 사용한 안압의 조절 |
US20110182848A1 (en) * | 2007-08-03 | 2011-07-28 | Asterion Limited | Granulocyte colony stimulating factor |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
ES2715177T3 (es) * | 2010-09-01 | 2019-06-03 | Genzyme Corp | Tratamiento de infarto de miocardio usando antagonistas de tgf-beta |
AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
ES2713505T3 (es) | 2013-03-11 | 2019-05-22 | Genzyme Corp | Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno |
JP6578271B2 (ja) * | 2013-04-17 | 2019-09-18 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 免疫抑制TGF−βシグナルコンバーター |
CA3008162A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
RS64053B1 (sr) * | 2015-10-30 | 2023-04-28 | Univ California | Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu |
CA3018382A1 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
CN108148863B (zh) | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
-
2016
- 2016-10-28 RS RS20230155A patent/RS64053B1/sr unknown
- 2016-10-28 WO PCT/US2016/059444 patent/WO2017075433A1/en active Application Filing
- 2016-10-28 JP JP2018522004A patent/JP7104624B2/ja active Active
- 2016-10-28 HU HUE16860930A patent/HUE061424T2/hu unknown
- 2016-10-28 FI FIEP16860930.3T patent/FI3368571T3/fi active
- 2016-10-28 LT LTEPPCT/US2016/059444T patent/LT3368571T/lt unknown
- 2016-10-28 CN CN201680077053.0A patent/CN108884155B/zh active Active
- 2016-10-28 ES ES16860930T patent/ES2935372T3/es active Active
- 2016-10-28 US US15/772,403 patent/US11014980B2/en active Active
- 2016-10-28 PL PL16860930.3T patent/PL3368571T3/pl unknown
- 2016-10-28 PT PT168609303T patent/PT3368571T/pt unknown
- 2016-10-28 CN CN202211444400.2A patent/CN115960264A/zh active Pending
- 2016-10-28 EP EP16860930.3A patent/EP3368571B1/en active Active
- 2016-10-28 EP EP22199829.7A patent/EP4169945A1/en active Pending
- 2016-10-28 SI SI201631648T patent/SI3368571T1/sl unknown
- 2016-10-28 KR KR1020187015353A patent/KR20180092947A/ko not_active Application Discontinuation
- 2016-10-28 HR HRP20230239TT patent/HRP20230239T1/hr unknown
- 2016-10-28 DK DK16860930.3T patent/DK3368571T3/da active
-
2021
- 2021-05-18 US US17/323,568 patent/US20210277099A1/en active Pending
-
2022
- 2022-07-08 JP JP2022110653A patent/JP2022141761A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7104624B2 (ja) | 2022-07-21 |
CN108884155B (zh) | 2022-12-06 |
CN115960264A (zh) | 2023-04-14 |
US20180312580A1 (en) | 2018-11-01 |
US11014980B2 (en) | 2021-05-25 |
WO2017075433A1 (en) | 2017-05-04 |
EP3368571A1 (en) | 2018-09-05 |
EP3368571B1 (en) | 2022-12-07 |
KR20180092947A (ko) | 2018-08-20 |
EP4169945A1 (en) | 2023-04-26 |
US20210277099A1 (en) | 2021-09-09 |
CN108884155A (zh) | 2018-11-23 |
JP2019500012A (ja) | 2019-01-10 |
JP2022141761A (ja) | 2022-09-29 |
SI3368571T1 (sl) | 2023-04-28 |
PL3368571T3 (pl) | 2023-05-02 |
LT3368571T (lt) | 2023-02-10 |
RS64053B1 (sr) | 2023-04-28 |
DK3368571T3 (da) | 2023-01-23 |
PT3368571T (pt) | 2023-01-03 |
EP3368571A4 (en) | 2019-11-06 |
HUE061424T2 (hu) | 2023-06-28 |
ES2935372T3 (es) | 2023-03-06 |
FI3368571T3 (fi) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230239T1 (hr) | Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu | |
JP2019500012A5 (hr) | ||
JP7465833B2 (ja) | Cd3反応性に基づくt細胞リクルートポリペプチド | |
CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
Zalfa et al. | Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy | |
ES2802994T3 (es) | Anticuerpo completamente humano contra CD137 humano y uso del mismo | |
Goedegebuure et al. | Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer | |
EP3055330B1 (en) | Molecule | |
CN111655716A (zh) | 基于il-15的与il-7和il-21的融合体 | |
WO2018197675A1 (en) | Ror1-specific chimeric antigen receptors (car) with humanized targeting domains | |
WO2021030688A1 (en) | Immunostimulatory multimeric binding molecules | |
RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
Han et al. | Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors | |
JP2022166297A (ja) | 最適化された多機能性t細胞を含むキメラ受容体t細胞を使用する治療 | |
US10927183B2 (en) | Anti-human VSIG4 antibodies and uses thereof | |
US20210252058A1 (en) | Chimeric antigen receptors with myd88 and cd40 costimulatory domains | |
CA3008440A1 (en) | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent | |
US20230312671A1 (en) | Grp78 targeted adoptive cell therapy | |
US20240216429A1 (en) | Chimeric antigen receptor system with adaptable receptor specificity | |
US20240216427A1 (en) | Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1) | |
KR20230160294A (ko) | Upar 항체 및 이를 갖는 융합 단백질 | |
CN113646328A (zh) | 一种免疫细胞因子及其制备与用途 | |
Mendoza-Valderrey et al. | Next generation immuno-oncology strategies: unleashing NK cells activity | |
WO2023129995A2 (en) | Chimeric antigen receptors comprising a pdz binding motif | |
WO2020094121A1 (en) | Novel method for producing antibodies |